Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 5977 - 5984 of 12128 results

TCPA Regulatory Update: FCC Evaluates Comments Received in Several TCPA Proceedings
July 18, 2018| Article| Viewpoint

TCPA Class Action Update: Post ACA International, the TCPA’s Autodialer Definition Is Restricted to a Device’s Current Functions
July 18, 2018| Article| Viewpoint

Court of Appeals Weighs in on 340B
July 18, 2018| Blog| Viewpoint

Recent ITC decision clarifies and eases domestic industry burden for patent holders
July 17, 2018| Blog| Viewpoint

July 2018: Where Are We Now With 340B?
July 17, 2018| Blog| Viewpoint

MintzEdge Entrepreneur Perspective: “Reinventing the Resume” - Co-Founders of Skillist
July 17, 2018| Podcast| Viewpoint

Retrogression of Employment Based First Preference Priority Date on August 1, 2018
July 16, 2018| Alert| Viewpoint

The Potential Pitfalls of Contesting Arbitrability in the Arbitration
July 16, 2018| News
News & Press Releases
Mintz Advises on LB Pharmaceuticals’ $285 Million Initial Public Offering
September 12, 2025
Mintz advised the underwriters in connection with a $285 million initial public offering by LB Pharmaceuticals Inc of 19,000,000 shares of common stock at an initial public offering price of $15.00 per share. The aggregate gross proceeds to LB Pharmaceuticals from this offering were approximately $285 million before deducting underwriting discounts and commissions and other offering expenses. In addition, LB Pharmaceuticals granted the underwriters a 30-day option to purchase up to an additional 2,850,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The shares began trading on the Nasdaq Global Market on September 11, 2025 under the ticker symbol “LBRX.”
Mintz Advises the Placement Agents in CAMP4’s up to $100 Million Private Placement
September 12, 2025
Mintz advised the placement agents in connection with CAMP4's up to $100 million private placement. The private placement included upfront gross proceeds of $50 million in exchange for common stock (and pre-funded warrants in lieu of common stock for certain investors). In addition, CAMP4 will be eligible to receive up to an additional $50 million in gross proceeds in exchange for common stock (and pre-funded warrants for certain investors), subject to achieving pre-specified milestones, including receipt of regulatory clearance to initiate a Phase 1/2 clinical trial in SYNGAP patients with its development candidate, CMP-SYNGAP-01.
Mintz Advises Premier Wealth Advisor Breed’s Hill Capital on Acquisition by Corient
September 12, 2025
Mintz represented Breed’s Hill Capital, a multi-family office overseeing approximately $3.5 billion in assets, in its acquisition by Corient, one of the nation’s leading wealth management firms. The transaction enhances Corient’s footprint in New England and advances its ability to deliver personalized fiduciary wealth management services across the region.
Events
Podcasts

Mintz On Air: Practical Policies – Disparage Me Not
August 26, 2025| Podcast|

Mintz On Air: Practical Policies - Investigations Unscripted
August 12, 2025| Podcast|

Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
